Loading
ImmunityBio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BLASZYK MICHAEL D, was filed 05 Jun 2023.
Insider Decl.
268
Thresholds
n/a
Buy Volume
€40M
11 ops. · all time
Sell Volume
€25M
101 ops. · all time
Who traded when
BuySaleBarry J. Simon7 sales
Christobel Selecky4 sales
Cheryl Cohen2 sales
Since the insiders bought
- +93.3%Entry US$3.29 · Close at T+365 US$6.36
- +93.3%Entry US$3.29 · Close at T+365 US$6.36
- +93.3%Entry US$3.29 · Close at T+365 US$6.36
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate ImmunityBio, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$14.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.64
Analyst consensus
4 analystsStrong buy
US$12.00Target US$14.25(+65%)US$16.00
Income statement
RevenueUS$113.3M
Gross profitUS$112.5M99% margin
EBITDA-US$223.6M-197% margin
Net income-US$351.4M-310.2% margin
Valuation
PER (forward)-117.8x
Beta0.03
Balance sheet & cash
Market capUS$9.2B
Total debtUS$518.1M
Free Cash Flow-US$309.2M
Profitability & ownership
ROA-30.5%
% insiders62.2%
% institutions19.8%
Last declaration on 6 October 2026
Declarations268 total
25,000 shares@ US$10.75040.0025% mcap2.1% of flowCommon StockSEC:0001326110-26-000085:0
55,979 shares@ US$2.980.0015% mcap5.7% of flowCommon StockSEC:0001326110-26-000084:0
81,056 shares@ US$10.500.0078% mcap29.1% of flowCommon StockSEC:0001326110-26-000084:1
560,000 shares@ US$13.67460.070% mcap61.3% of flowCOMMONSEC144:0001949846-26-000605
81,056 shares@ US$9.280.0076% mcap100.0% of flowCommonSEC144:0001950047-26-010013
55,979 shares@ US$2.980.0018% mcap8.6% of flowCommon StockSEC:0001529371-26-000008:0
131,210 shares@ US$9.50340.014% mcap64.3% of flowCommon StockSEC:0001529371-26-000008:1
35,064 shares@ US$2.980.0011% mcap4.9% of flowCommon StockSEC:0001849739-26-000014:0
124,414 shares@ US$2.990.0041% mcap17.4% of flowCommon StockSEC:0001849739-26-000014:1
159,478 shares@ US$9.02360.016% mcap67.5% of flowCommon StockSEC:0001849739-26-000014:2
131,210 shares@ US$9.200.013% mcap100.0% of flowCommonSEC144:0001950047-26-006831
159,478 shares@ US$8.7550.015% mcap62.5% of flowCommonSEC144:0001950047-26-006714
1,000 shares@ US$8.770.0001% mcap0.4% of flowCommonSEC144:0001950047-26-006655
95,722 shares@ US$8.710.0091% mcap37.2% of flowCommonSEC144:0001950047-26-006608
25,000 shares@ US$7.87631.5% of flowCommon StockSEC:0001647994-26-000011:0
268,033 shares@ US$10.9930.035% mcap59.0% of flowCOMMONSEC144:0001949846-26-000345
4,606,596 shares@ US$5.4275.1% of flowCommon StockSEC:0001189020-26-000008:0
75,000 shares@ US$12.01050.0091% mcap17.7% of flowCommon StockSEC:0001647994-26-000006:0
15,243 shares0Common StockSEC:0001647994-26-000004:1
58,170 shares@ US$8.700.1% of flowCommon StockSEC:0001189020-26-000006:1
25,000 shares@ US$10.008.4% of flowCommon StockSEC:0001849739-26-000004:1
6,026 shares@ US$8.700.2% of flowCommon StockSEC:0001647994-26-000004:2
165,000 shares@ US$10.255.4% of flowCommon StockSEC:0001647994-26-000004:3
20,682 shares@ US$8.7023.6% of flowCommon StockSEC:0001848899-26-000005:1
1,673 shares@ US$8.7013.3% of flowCommon StockSEC:0001200637-26-000004:1
25 of 268 declarations
About ImmunityBio, Inc.
A single purchase shapes ImmunityBio, Inc.'s figures: Patrick Soon-Shiong, Chairman and CEO, bought EUR 39,979,009 on June 29, 2020, nearly the whole EUR 40.3 million of the record's 11 purchases. The others are small: Michael D. Blaszyk, a director, EUR 124,125 on June 5, 2023, and Michael D. Blaszyk, a director, EUR 59,495 on June 5, 2023. Between June 1, 2023 and June 5, 2023, 3 filers bought EUR 269,496.
Against that, 101 sales weigh EUR 25.2 million, median EUR 120,323, or 10% purchases among open-market trades. The largest are Barry J. Simon's: EUR 1,917,645 on December 22, 2020 and EUR 1,740,684 on July 20, 2020; Barry J. Simon, a director, EUR 1,429,056 on February 23, 2026. Steve Gorlin (Director) is the top filer, with 38 filings, 36 of them sales.
Read moreShow less
A US health care company listed on Nasdaq (USD 8.92 billion) in which insiders hold 62.2% of the capital. 268 filings from 21 filers, 79 option exercises and 52 grants. The volume is 50 filings in 2026 against 3 in 2022. Last twelve months: 50 filings, 13 sales, no purchase.
